Servier India introduces ‘Ivosidenib’(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
Marks an important development in oncology, providing a treatment option for patients with AML and cholangiocarcinoma in India....
June 5, 2025